PharmaTher Reports Results of Ketamine in a Clinical Study for the Treatment of Parkinson’s Disease
Shots:
- The company reported the results from the dose-finding & tolerability clinical study that evaluates ketamine for the treatment of LID in patients with PD
- In an efficacy result, 100% of patients treated with ketamine showed a reduction in dyskinesias as measured by the UDysRS over pre-treatment baseline, was well tolerated with no serious AEs. The results are expected to be submitted for presentation at a medical congress by June 2022
- The company plans to advance the P-III study, based on these results & plans to engage with the US FDA for the ketamine’s approval in a planned P-III clinical study to treat PD under the 505(b)(2) regulatory pathway
Ref: Globe Newswire | Image: Globe Newswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
